0001209191-23-019656.txt : 20230317
0001209191-23-019656.hdr.sgml : 20230317
20230317163353
ACCESSION NUMBER: 0001209191-23-019656
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230315
FILED AS OF DATE: 20230317
DATE AS OF CHANGE: 20230317
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nash Huw M.
CENTRAL INDEX KEY: 0001780085
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38938
FILM NUMBER: 23743134
MAIL ADDRESS:
STREET 1: C/O STOKE THERAPEUTICS, INC.
STREET 2: 45 WIGGINS AVE
CITY: BEDFORD
STATE: MA
ZIP: 01730
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Stoke Therapeutics, Inc.
CENTRAL INDEX KEY: 0001623526
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 471144582
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 45 WIGGINS AVENUE
CITY: BEDFORD
STATE: MA
ZIP: 01730
BUSINESS PHONE: 781-430-8200
MAIL ADDRESS:
STREET 1: 45 WIGGINS AVENUE
CITY: BEDFORD
STATE: MA
ZIP: 01730
FORMER COMPANY:
FORMER CONFORMED NAME: ASOthera Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20141028
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-03-15
0
0001623526
Stoke Therapeutics, Inc.
STOK
0001780085
Nash Huw M.
C/O STOKE THERAPEUTICS, INC.
45 WIGGINS AVENUE
BEDFORD
MA
01730
0
1
0
0
COO & CBO
Employee Stock Option (Right to Buy)
9.15
2023-03-15
4
A
0
78600
0.00
A
2033-03-14
Common Stock
78600
78600
D
Restricted Stock Unit (RSU)
2023-03-15
4
A
0
52400
0.00
A
2027-03-15
Common Stock
52400
52400
D
The option vests as to 1/48th of the total shares on April 15, 2023 and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
The RSUs vest as to 1/4th of the total shares annually beginning March 15, 2024, subject to the reporting person's continued service to the issuer through each vesting date.
/s/ Stephen Tulipano, Attorney-in-Fact
2023-03-17